Tokyo, June 15, 2010 (JCN) - Asahi Kasei Pharma and Novartis Pharma have concluded a license agreement for zoledronic acid, a bisphosphonate agent used for the treatment of osteoporosis.
Under the terms of the agreement, Asahi Kasei Pharma obtains exclusive rights in Japan to develop and sell zoledronic acid for the treatment of osteoporosis, and will begin clinical development of this agent in Japan.
Zoledronic acid is used to treat osteoporosis in many countries, and Novartis Pharma has been looking forward to making the product available to meet the needs of Japanese patients.
With many years of experience and a strong established track record in the field of bone metabolism disorders, notably with its Elcitonin treatment for osteoporosis pain, Asahi Kasei Pharma had sought to further reinforce its development pipeline in this field. As such, the two companies shared complimentary interests, which led to the conclusion of this license agreement.
It is estimated that more than 10 million people suffer from osteoporosis in Japan, including those not receiving treatment,* and the number is increasing as the population ages.
Since osteoporosis carries an increased risk of vertebral and femoral neck fracture, with a high probability of resulting in confinement to bed, the implementation of effective measures against osteoporosis is not only a medical matter but also an important social issue.
Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.
 Company Profile |  Print |  Alerts
|
 |
|
Asahi Kasei Establishes Base in India
(Feb 25, 2013)
|
|
|
Asahi Kasei Chemicals Opens AN and MMA Plants in Thailand
(Feb 14, 2013)
|
|
|
Asahi Kasei Completes Construction of Kawasaki Innovation Center
(Dec 3, 2012)
|
|
|
ZOLL Medical Sets Up Japan Subsidiary
(Oct 26, 2012)
|
|
|
Asahi Kasei Microdevices Launches New 3-axis Electronic Compass for Mobile Devices
(July 23, 2012)
|
|
|
Asahi Kasei Medical Takes Equity Stake in NxStage Medical
(May 10, 2012)
|
|
|
Asahi Kasei Commences Tender Offer for ZOLL
(Mar 29, 2012)
|
|
|
Asahi Kasei to Acquire ZOLL Medical
(Mar 14, 2012)
|
|
|
Asahi Kasei Chemicals and Daiso Dissolves JV
(Mar 12, 2012)
|
|
|
Asahi Kasei to Construct Acetonitrile Plant in South Korea
(Mar 6, 2012)
|
|
|
